Serotonin 5-HT1 Receptor Agonists
"Serotonin 5-HT1 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.
| Descriptor ID |
D058825
|
| MeSH Number(s) |
D27.505.519.625.850.800.100 D27.505.696.577.850.800.100
|
| Concept/Terms |
Serotonin 5-HT1 Receptor Agonists- Serotonin 5-HT1 Receptor Agonists
- Serotonin 5 HT1 Receptor Agonists
- 5-HT1 Agonist
- 5 HT1 Agonist
- Agonist, 5-HT1
- 5-HT1 Agonists
- 5 HT1 Agonists
- Agonists, 5-HT1
Serotonin 5-HT1B-D Agonists- Serotonin 5-HT1B-D Agonists
- 5-HT1B-D Agonists, Serotonin
- Agonists, Serotonin 5-HT1B-D
- Serotonin 5 HT1B D Agonists
- 5-HT1B-D Agonist
- 5 HT1B D Agonist
- Agonist, 5-HT1B-D
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT1 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT1 Receptor Agonists".
This graph shows the total number of publications written about "Serotonin 5-HT1 Receptor Agonists" by people in this website by year, and whether "Serotonin 5-HT1 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin 5-HT1 Receptor Agonists" by people in Profiles.
-
Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE, Dodick DW. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022 Apr 25; 23(1):50.
-
Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache. 2019 04; 59(4):509-517.
-
Dodick DW, Tepper SJ, Friedman DI, Gelfand AA, Kellerman DJ, Schmidt PC. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial. Headache. 2018 Jul; 58(7):986-992.
-
Silberstein SD. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Expert Opin Drug Saf. 2018 Jan; 17(1):89-97.
-
Spierings EL, Brandes JL, Kudrow DB, Weintraub J, Schmidt PC, Kellerman DJ, Tepper SJ. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia. 2018 02; 38(2):215-224.
-
Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014 Feb; 171(3):636-45.
-
Tepper SJ, Chen S, Reidenbach F, Rapoport AM. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013 Sep; 53 Suppl 2:62-71.
-
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014 Feb; 34(2):114-25.
-
Tepper SJ. Clinical implications for breath-powered powder sumatriptan intranasal treatment. Headache. 2013 Sep; 53(8):1341-9.
-
Olsen AS, Sozda CN, Cheng JP, Hoffman AN, Kline AE. Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone. J Neurotrauma. 2012 Jul 01; 29(10):1898-907.